{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T11:40:44Z","timestamp":1654602044362},"reference-count":0,"publisher":"American Association for Cancer Research (AACR)","issue":"6","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>According to results from the phase III CHRONOS-3 trial, patients with relapsed indolent non\u2013Hodgkin lymphoma may benefit significantly from the addition of copanlisib, a pan-PI3K inhibitor, to standard rituximab. The combination was safe and nearly halved the risk of disease progression or death, compared with placebo and rituximab.<\/jats:p>","DOI":"10.1158\/2159-8290.cd-nb2021-0331","type":"journal-article","created":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T13:51:53Z","timestamp":1618062713000},"page":"OF2-OF2","update-policy":"http:\/\/dx.doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["NHL Progression Risk Cut with Copanlisib\u2013Rituximab Combo"],"prefix":"10.1158","volume":"11","member":"1086","published-online":{"date-parts":[[2021,4,9]]},"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/11\/6\/OF2\/666619\/NHL-Progression-Risk-Cut-with-Copanlisib-Rituximab","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/11\/6\/OF2\/666619\/NHL-Progression-Risk-Cut-with-Copanlisib-Rituximab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T11:16:56Z","timestamp":1654600616000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/11\/6\/OF2\/666619\/NHL-Progression-Risk-Cut-with-Copanlisib-Rituximab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,9]]},"references-count":0,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,4,9]]},"published-print":{"date-parts":[[2021,6,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-nb2021-0331","relation":{},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,9]]}}}